Journal article
Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): A 3-year follow-up study in community patients
SS Xu, PK Alexander, Y Lie, V Dore, S Bozinovski, RS Mulligan, K Young, VL Villemagne, CC Rowe
BMJ Open | BMJ PUBLISHING GROUP | Published : 2018
Abstract
Objectives To further validate the diagnostic utility of 18 F-AV-133 vesicular monoamine transporter type 2 (VMAT2) positron emission tomography (PET) in patients with clinically uncertain parkinsonian syndromes (CUPS) by comparison to clinical diagnosis at 3 years follow-up. Design, setting and participants In a previous study, we reported that 18 F-AV-133 PET in community patients with CUPS changed diagnosis and management and increased diagnostic confidence. The current diagnosis of this cohort was obtained from the patient and treating specialist and compared with the diagnosis suggested 3 years earlier by the 18 F-AV-133 PET. A second 18 F-AV-133 PET was available in those with a discor..
View full abstractGrants
Funding Acknowledgements
This was an investigator-initiated study supported by a grant from Avid Radiopharmaceuticals. CCR has received research grants for imaging in dementia from Piramal Imaging, GE Healthcare, Cerveau, Astra Zeneca, Biogen and Navidea. He has been a consultant or paid speaker at sponsored conference sessions for Piramal Imaging, GE Healthcare, Astra Zeneca, Roche and Biogen. VLV has been a consultant or paid speaker at sponsored conference sessions for Piramal Imaging, GE Healthcare, Astra Zeneca and Novartis.